Scynexis (SCYX) Enterprise Value (2014 - 2026)
Scynexis' (SCYX) quarterly Enterprise Value came in at -$74.2 million in Q2 2026, down 58.9% on a YoY basis from -$180.5 million in Q2 2025, and down 53.72% quarter-over-quarter from -$48.3 million in Q1 2026.
Analysis
Scynexis (SCYX) Enterprise Value (2014 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Enterprise Value for 13 consecutive years, with -$74.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Enterprise Value fell 58.9% year-over-year to -$74.2 million; the trailing twelve-month figure through Jun 2026 stood at -$74.2 million (down 58.9% YoY), and the FY2025 full-year result was -$12.5 million, down 1985.59% from the prior year.
- Enterprise Value fell to -$74.2 million in Q2 2026 per SCYX's latest filing, from -$48.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at $60.6 million in Q1 2023 and bottomed at -$74.2 million in Q2 2026.
- Historically, Enterprise Value has averaged -$20.4 million across 5 years, with a median of -$31.2 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 560.44% in 2023, then slumped 1985.59% in 2025.
- Over 5 years, Enterprise Value stood at -$7.0 million in 2022, then soared by 560.44% to $32.3 million in 2023, then slumped by 101.85% to -$599181.0 in 2024, then plunged by 1985.59% to -$12.5 million in 2025, then slumped by 493.78% to -$74.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$74.2 million, -$48.3 million, and -$12.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -74.20 Mn |
| Mar 31, 2026 | -48.27 Mn |
| Dec 31, 2025 | -12.50 Mn |
| Sep 30, 2025 | -28.72 Mn |
| Jun 30, 2025 | -46.70 Mn |
| Mar 31, 2025 | -40.40 Mn |
| Dec 31, 2024 | -599,181.03 |
| Sep 30, 2024 | -52.56 Mn |
| Jun 30, 2024 | -33.72 Mn |
| Mar 31, 2024 | -68.04 Mn |
| Dec 31, 2023 | 32.35 Mn |
| Sep 30, 2023 | -40.01 Mn |
| Jun 30, 2023 | 21.58 Mn |
| Mar 31, 2023 | 60.56 Mn |
| Dec 31, 2022 | -7.03 Mn |
| Sep 30, 2022 | -9.56 Mn |
| Jun 30, 2022 | -38.19 Mn |
| Mar 31, 2022 | 19.04 Mn |
| Dec 31, 2021 | 70.62 Mn |
| Sep 30, 2021 | 26.48 Mn |